Inflammatory Mechanisms in Diabetic Kidney Disease

Diabetic kidney disease arises from a complex interplay between metabolic dysregulation and immune activation within the renal microenvironment. Persistent hyperglycaemia triggers oxidative stress and the generation of advanced glycation end-products, which in turn activate resident renal cells and recruit circulating leukocytes. Key pathways include Toll-like receptor signalling, nuclear factor-κB (NF-κB) activation and JAK–STAT cascades, each driving the release of proinflammatory cytokines and chemokines. Infiltrating macrophages and T lymphocytes amplify local inflammation, promoting mesangial expansion, podocyte injury and tubular interstitial fibrosis. Endothelial dysfunction further exacerbates capillary rarefaction and glomerular hypertension, accelerating loss of glomerular filtration rate. Over time, the chronic inflammatory milieu induces extracellular matrix deposition and scarring, ultimately leading to end-stage renal failure. Understanding these mechanisms has underpinned the development of targeted anti-inflammatory strategies aimed at slowing disease progression and reducing global burden.

Research from Nature Portfolio

Recent work has elucidated a novel mechanism by which angiotensin II promotes kidney inflammation and fibrosis through direct interaction with myeloid differentiation protein 2 (MD2), the accessory protein of Toll-like receptor 4. In experimental models, blockade or genetic deletion of MD2 prevented angiotensin II-induced NF-κB and ERK activation, reduced pro-inflammatory and pro-fibrotic gene expression, and preserved renal function. These findings identify MD2 as a critical mediator of innate immune signalling in diabetic renal injury and suggest that specific MD2 inhibitors could represent a therapeutic strategy to mitigate inflammation-driven fibrosis in diabetic kidney disease.

Inflammatory Mechanisms in Diabetic Kidney Disease publication trend

The graph below shows the total number of articles in inflammatory mechanisms in diabetic kidney disease across all publications each year (not limited to Nature Index journals).

Technical terms

Advanced glycation end-products: Molecules formed by non-enzymatic reaction of sugars with proteins or lipids, which promote oxidative stress and inflammation.

Cytokine: Small secreted protein that mediates and regulates immunity and inflammation.

Toll-like receptor 4 (TLR4): A pattern-recognition receptor that detects endogenous and exogenous ligands, initiating innate immune responses.

MD2: Accessory protein that associates with TLR4 to enable recognition of specific ligands and trigger downstream signalling.

Nuclear factor-κB (NF-κB): Transcription factor that controls expression of many proinflammatory genes.

Systemic immune-inflammation index (SII): Biomarker derived from counts of platelets, neutrophils and lymphocytes reflecting systemic inflammatory status.

Neutrophil-to-lymphocyte ratio (NLR): Simple marker of systemic inflammation based on the relative counts of neutrophils and lymphocytes.

References

1. Inflammation in Diabetic Nephropathy. Mediators of Inflammation (2012).
2. Angiotensin II induces kidney inflammatory injury and fibrosis through binding to myeloid differentiation protein-2 (MD2). Scientific Reports (2017).
3. Systemic immune-inflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: Evidence from NHANES 2011-2018. Frontiers in Endocrinology (2022).
4. Associations between the Neutrophil‐to‐Lymphocyte Ratio and Diabetic Complications in Adults with Diabetes: A Cross‐Sectional Study. Journal of Diabetes Research (2020).
5. Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction. Cell Communication and Signaling (2023).